



Media Contacts:

ANAGENESIS BIOTHERAPIES INC.:

Jean-Yves Bonnefoy

President and CEO

Email : jybonnefoy@anagenesis-biotech.com

MLSC

Angus McQuilken

Vice President for Communications & Marketing

Massachusetts Life Sciences Center

Phone: (617) 921-7749

E-mail: amcquilken@masslifesciences.com

FOR IMMEDIATE RELEASE:

April 19th, 2016

Anagenesis Biotechnologies launches its US subsidiary, Anagenesis Biotherapies Inc. in Boston, Massachusetts to carry out its cell therapy programs

Strasbourg, France, April 19, 2016 - Anagenesis Biotechnologies, a company developing stem cell-derived treatments for muscle diseases, announced today the creation of its US subsidiary, Anagenesis Biotherapies Inc. with offices at the Cambridge Innovation Center's 50 Milk Street facility in Boston, Massachusetts. The US subsidiary will carry out the company's cell therapy programs with an initial focus on Duchenne Muscular Dystrophy (DMD), paving the way for future partnerships.

Anagenesis owns a unique stem cell differentiation technology that allows the massive and standardized production of different lineages including mature skeletal muscle cells. Using this technology, the company is currently developing two R&D programs for muscle disorders:

- Cell therapy for DMD
- High Throughput/High Content Screening using customized in vitro assays to identify lead compounds acting on muscle progenitors for sarcopenia and cachexia, two muscle disorders associated with aging and cancer, respectively.

"Massachusetts' position at the vanguard of stem cell research attracts talent, investment, and partners from across the world," said Governor Charlie Baker. "Massachusetts is a clear choice for Anagenesis to establish a presence in the United States, and we are confident this decision will maximize their growth, and advance their important work on behalf of patients with muscular dystrophy and other muscle diseases."

Following the publication of Anagenesis' technology in Nature Biotechnology last August, the company has been actively involved in discussions with US-based biopharma and patient associations. The establishment of Anagenesis' operations in Massachusetts will allow the company to come closer to its future partners and constitutes a strategic step to advance the company's DMD cell therapy program.

Jean-Yves Bonnefoy, Anagenesis President and CEO, commented "We are very excited to become part of this exceptional biotechnology and academic cluster. Massachusetts is the ideal location for us to advance our DMD cell therapy product candidate, which has unique advantages over other therapies currently under development. Indeed, the local strength in stem cell research will greatly benefit the cell therapy focus of our US-subsiary and also will help us expand our product candidate portfolio to brown fat or cartilage-based therapies to address other diseases druggable by our technology".

"We are excited to welcome Anagenesis to the Massachusetts Life Sciences ecosystem," said Travis McCready President & CEO of the Massachusetts Life Sciences Center. "They are joining a vibrant and growing cluster of companies here that are working on new therapies for muscle disorders such as Duchenne Muscular Dystrophy. We look forward to being good partners with Anagenesis as they put down roots and grow in Massachusetts."

"We are thrilled to welcome Anagenesis to the Massachusetts life sciences supercluster," said Robert K. Coughlin, President & CEO of MassBio. "We know they will bring value to and benefit from our robust research community as they develop new partnerships and advance their cell therapy programs."

About Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is an X-linked rare degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. One of the most common fatal genetic disorders, DMD affects approximately one in every 3,500 boys born worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with mutations in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Progressive muscle weakness in the lower limbs spreads to the arms, neck and other areas. Eventually, increased difficulty in breathing due to respiratory muscles dysfunction requires ventilation support, and cardiac dysfunction can lead to heart failure. The condition is universally fatal, and death usually occurs before the age of 35.

About Anagenesis Biotechnologies

Anagenesis Biotechnologies is a private company developing new treatments against muscle diseases (genetic such as DMD and chronic such as sarcopenia and cachexia). The company was cofounded by Pr. Olivier Pourquié, a worldwide key opinion leader in the field of musculoskeletal development and stem cells. Olivier Pourquié is a Professor at Harvard Medical School and the Brigham and Women's Hospital and a member of the Harvard Stem Cell Institute. Anagenesis is managed by its President & CEO, Dr Jean-Yves Bonnefoy who comes from the Pharma & Biotech industry and brings to the team his experience in the field of pharmaceutical development. For more information: www.anagenesis-biotech.com.

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, \$1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation's most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information, visit www.masslifesciences.com.

This announcement is not intended to be a commercial endorsement by the MLSC of any products or services provided or developed by the entities referenced in this release

###